Compared with de novo myeloid neoplasms, t-MNs carry higher rates of complex karyotype (30–50%), somatic TP53 variants (15–40%), and abnormalities in chromosomes 5 and 7 (Baranwal et al., 2022; Wong et al., 2014). The gene discussed is TP53; the disease is myeloid neoplasm.